Your browser doesn't support javascript.
loading
Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression
Acta Pharmaceutica Sinica B ; (6): 4008-4019, 2021.
Article in English | WPRIM | ID: wpr-922456
ABSTRACT
Cholangiocarcinoma (CCA) has emerged as an intractable cancer with scanty therapeutic regimens. The aberrant activation of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are reported to be common in CCA patients. However, the underpinning mechanism remains poorly understood. Deubiquitinase (DUB) is regarded as a main orchestrator in maintaining protein homeostasis. Here, we identified Josephin domain-containing protein 2 (JOSD2) as an essential DUB of YAP/TAZ that sustained the protein level through cleavage of polyubiquitin chains in a deubiquitinase activity-dependent manner. The depletion of JOSD2 promoted YAP/TAZ proteasomal degradation and significantly impeded CCA proliferation

Full text: Available Index: WPRIM (Western Pacific) Type of study: Prognostic study Language: English Journal: Acta Pharmaceutica Sinica B Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Prognostic study Language: English Journal: Acta Pharmaceutica Sinica B Year: 2021 Type: Article